Latest Lucentis Stories
Two drugs commonly used to treat age-related macular degeneration (AMD) yield similar improvements in vision for patients receiving treatments on a monthly or as-needed basis.
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease.
ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.
INCLINE VILLAGE, Nev., June 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc.